Shah HR - Search Results

1

PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies.

Salem AE, Shah HR, Covington MF, Koppula BR, Fine GC, Wiggins RH, Hoffman JM, Morton KA. Salem AE, et al. Among authors: shah hr. Cancers (Basel). 2022 Nov 30;14(23):5941. doi: 10.3390/cancers14235941. Cancers (Basel). 2022. PMID: 36497423 Free PMC article. Review.

2

Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center.

Shah H, Kim S, Klimecki S, Charlson K, Uberti J, Schiffer CA, Fiala MA, Seymour E. Shah H, et al. Bone Marrow Transplant. 2022 Jul;57(7):1213-1215. doi: 10.1038/s41409-022-01706-6. Epub 2022 May 17. Bone Marrow Transplant. 2022. PMID: 35581406 Free PMC article. No abstract available.

3

Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy.

Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK. Rock CB, et al. Among authors: shah hr. Adv Radiat Oncol. 2022 Jul 26;7(6):101035. doi: 10.1016/j.adro.2022.101035. eCollection 2022 Nov-Dec. Adv Radiat Oncol. 2022. PMID: 36420188 Free PMC article.

4

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.

Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA. Stephens DM, et al. Clin Cancer Res. 2022 Aug 2;28(15):3242-3247. doi: 10.1158/1078-0432.CCR-21-3867. Clin Cancer Res. 2022. PMID: 35608822 Free PMC article. Clinical Trial.

5

Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.

Shah H, Stephens D, Seymour J, Maddocks K. Shah H, et al. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-18. doi: 10.1200/EDBK_320117. Am Soc Clin Oncol Educ Book. 2021. PMID: 33770460 Free article.

6

Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality.

Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK. Parsons MW, et al. Among authors: shah hr. Cancer Med. 2023 Feb;12(3):2624-2636. doi: 10.1002/cam4.5139. Epub 2022 Aug 17. Cancer Med. 2023. PMID: 36812123 Free PMC article.

7

The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021.

Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. Goyal G, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2316642. doi: 10.1001/jamanetworkopen.2023.16642. JAMA Netw Open. 2023. PMID: 37273206 Free PMC article.

8

Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia.

Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM. Vardell VA, et al. Among authors: shah hr. Am J Hematol. 2023 Jul;98(7):E172-E174. doi: 10.1002/ajh.26937. Epub 2023 Apr 20. Am J Hematol. 2023. PMID: 37078687

9

T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.

Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM. Vardell VA, et al. Am J Hematol. 2024 Mar;99(3):494-496. doi: 10.1002/ajh.27205. Epub 2024 Jan 19. Am J Hematol. 2024. PMID: 38240336

10

Is there a role for anti-CD20 antibodies in CLL?

Shah HR, Stephens DM. Shah HR, et al. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):68-75. doi: 10.1182/hematology.2021000234. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889417 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page